Sans-De San Nicolas, L, Figueras-Nart, I, Bonfill-Orti, M, De Jesus-Gil, C, Garcia-Jimenez, I, Guilabert, A, Curto-Barredo, L, Bertolin-Colilla, M, Ferran, M, Serra-Baldrich, E, Zalewska-Janowska, A, Wang, YH, Howell, MD, Pujol, RM, Santamaria-Babi, LF. SEB-induced IL-13 production in CLA(+) memory T cells defines Th2 high and Th2 low responders in atopic dermatitis. ALLERGY. 2022; 77(11)DOI:10.1111/all.15424. PMID:35773619. IF:12.400(Q1/1D).

Le, AM, Puig, L, Torres, T. Deucravacitinib for the Treatment of Psoriatic Disease. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY. 2022; 23(6)DOI:10.1007/s40257-022-00720-0. PMID:35960487. IF:7.300(Q1/1D).

Torres, T, Puig, L, Vender, R, Yeung, J, Carrascosa, JM, Piaserico, S, Gisondi, P, Lynde, C, Ferreira, P, Bastos, PM, Dauden, E, Leite, L, Valerio, J, del Alcazar-Viladomiu, E, Rull, EV, Llamas-Velasco, M, Pirro, F, Messina, F, Bruni, M, Licata, G, Ricceri, F, Nidegger, A, Hugo, J, Mufti, A, Daponte, AI, Teixeira, L, Balato, A, Romanelli, M, Prignano, F, Gkalpakiotis, S, Conrad, C, Lazaridou, E, Rompoti, N, Papoutsaki, M, Nogueira, M, Chiricozzi, A. Drug Survival of Interleukin (IL)-17 and IL-23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi-country, Multicentric Cohort Study. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY. 2022; 23(6)DOI:10.1007/s40257-022-00722-y. PMID:35976568. IF:7.300(Q1/1D).

Wollenberg, A, Kinberger, M, Arents, B, Aszodi, N, Valle, GA, Barbarot, S, Bieber, T, Brough, HA, Pinton, PC, Christen-Zach, S, Deleuran, M, Dittmann, M, Dressler, C, Fink-Wagner, AH, Fosse, N, Gaspar, K, Gerbens, L, Gieler, U, Girolomoni, G, Gregoriou, S, Mortz, CG, Nast, A, Nygaard, U, Redding, M, Rehbinder, EM, Ring, J, Rossi, M, Serra-Baldrich, E, Simon, D, Szalai, ZZ, Szepietowski, JC, Torrelo, A, Werfel, T, Flohr, C. European guideline (EuroGuiDerm) on atopic eczema - part II: non-systemic treatments and treatment recommendations for special AE patient populations. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2022; 36(11)DOI:10.1111/jdv.18429. PMID:36056736. IF:9.200(Q1/1D).

Thaci, D, Gerdes, S, Du Jardin, KG, Perrot, JL, Puig, L. Efficacy of Tildrakizumab Across Different Body Weights in Moderate-to-Severe Psoriasis Over 5 Years: Pooled Analyses from the reSURFACE Pivotal Studies. Dermatology and Therapy. 2022; 12(10)DOI:10.1007/s13555-022-00793-z. PMID:36098877. IF:3.400(Q2/3D).

Wollenberg, A, Kinberger, M, Arents, B, Aszodi, N, Valle, GA, Barbarot, S, Bieber, T, Brough, HA, Pinton, PC, Christen-Zach, S, Deleuran, M, Dittmann, M, Dressler, C, Fink-Wagner, AH, Fosse, N, Gaspar, K, Gerbens, L, Gieler, U, Girolomoni, G, Gregoriou, S, Mortz, CG, Nast, A, Nygaard, U, Redding, M, Rehbinder, EM, Ring, J, Rossi, M, Serra-Baldrich, E, Simon, D, Szalai, ZZ, Szepietowski, JC, Torrelo, A, Werfel, T, Flohr, C. European guideline (EuroGuiDerm) on atopic eczema: part I - systemic therapy. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2022; 36(9)DOI:10.1111/jdv.18345. PMID:35980214. IF:9.200(Q1/1D).

Piron, M, Salvador, F, Caballero, E, Sanchez-Montalva, A, Bes, M, Casamitjana, N, Puig, L, Molina, I, Sauleda, S. HTLV-1/2 Infection in Blood Donors from a Non-Endemic Area (Catalonia, Spain) between 2008 and 2017: A 10-Year Experience. Viruses-Basel. 2022; 14(9)DOI:10.3390/v14091975. PMID:36146780. IF:4.700(Q2/5D).

Zozaya, N, Abdalla, F, Zamora, SA, Filgueiras, JB, Carrillo, JMC, Sanchez, OD, Sinisterra, FD, Garcia-Ruiz, A, Pinto, PH, Manfredi, A, Olmos, JM, Luna, PMD, Puig, L, Ros, S, HIdalgo-Vega, A. Assessing the value contribution of bimekizumab for the treatment of moderate-to-severe psoriasis using a multidisciplinary reflective multi-criteria decision analysis. Expert Review of Pharmacoeconomics & Outcomes Research. 2022; 22(6)DOI:10.1080/14737167.2022.2063842. PMID:35404728. IF:2.300(Q3/7D).